KKRC
INSM icon

Kohlberg Kravis Roberts & Co’s Insmed INSM Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,284
Closed -$473K – 93
2025
Q3 		$473K Hold
3,284
– – 0.01% 81
2025
Q2 		$331K Buy
+3,284
New +$251K 0.01% 72

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's INSM Position: Q4 2025 in Review

Kohlberg Kravis Roberts & Co sold out of Insmed (INSM) in Q4 2025, closing a stake of 3,284 shares — an estimated $473K sold.

Kohlberg Kravis Roberts & Co first reported a position in INSM in Q2 2025 and held it in 2 quarters. The position peaked at $473K in Q3 2025. 677 funds tracked by Wall St. Rank hold INSM as of Q4 2025.

  • Kohlberg Kravis Roberts & Co reported no remaining Insmed position as of Q4 2025 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 3,284 Insmed shares in Q4 2025, an estimated $473K.
  • Kohlberg Kravis Roberts & Co first reported a position in Insmed in Q2 2025 and held it in 2 quarters.
  • Kohlberg Kravis Roberts & Co's Insmed position peaked at $473K in Q3 2025.
  • 677 funds tracked by Wall St. Rank held Insmed as of Q4 2025.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q4 2025, filed 17 Feb 2026.